Authors
Latest:
Face-Off: Award Presentation CeremonyFollowing a spirited debate, Joshua K. Sabari, MD, presents the winning team with the coveted title of victors of this CancerNetwork® Face-Off event.
Latest:
Impact of T-cell Affinity in Bispecific Therapy in R/R MMNoopur Raje, MD, discusses the role of T-cell affinity in bispecific therapy for patients with relapsed/refractory multiple myeloma and how it impacts treatment practices.
Latest:
Unusual Clinical Presentation of Clear Cell Sarcoma in a Young WomanA young woman presents with painless lumps to the emergency department and is later diagnosed with clear cell carcinoma.
Latest:
Current Frontline Treatment of Diffuse Large B-Cell LymphomaThis review article discusses which frontline treatment are best for diffuse large B-cell lymphoma.
Latest:
The Post–CAR T Journey: Long-Term Monitoring, Multidisciplinary Care, and Continuous Patient SupportPanelists discuss how health care centers provide comprehensive long-term monitoring and support services for both patients receiving CAR T and their caregivers in the posttreatment period, including regular medical assessments and ongoing educational resources.
Latest:
Radiation Oncology Remains ‘Third Leg of the Stool’ in Cancer Treatment, But Continues to Be SuccessfulThe emergence of using hypofractionated radiation treatments—fewer radiation treatments at larger doses—across cancer types may place financial strain on radiation oncologists, but one expert notes there’s still continued success.
Latest:
Decisional Capacity Determination in Patients With CancerExperts discuss the process of assessing decision-making capacity in patients with cancer.
Latest:
Expert Reviews Alternative Treatment Options in Muscle-Invasive Bladder CancerShilpa Gupta, MD, shares the current standard of care for muscle-invasive bladder cancer and highlights other options that may be suitable for some patients.
Latest:
Secondary Pure Red Cell Aplasia During Daratumumab/ Hyaluronidase Therapy for Multiple MyelomaInvestigators discussed the potential link between secondary pure red cell aplasia and subcutaneous daratumumab/hyaluronidase formulation for multiple myeloma.
Latest:
Omidubicel Can ‘Improve Outcomes’ in Blood Cancer Needing UCB TransplantCorey Cutler, MD, MPH, FRCPC, discusses how patients with blood cancer in need of an umbilical cord blood transplant may benefit from omidubicel-onlv.
Latest:
Neoadjuvant Capecitabine Plus Temozolomide in Atypical Lung NETsRead about a woman with well-differentiated atypical carcinoid who experienced a 21% regression in primary tumor size after 12 months on neoadjuvant capecitabine and temozolomide.
Latest:
Navigating a Paradigm Shift Venetoclax Treatment Redefines Landscape of Acute Myeloid LeukemiaInvestigators focused on the latest advances in the treatment of patients with AML, while prioritizing the use of venetoclax as it has been shown to significantly impact the course of the disease.
Latest:
Treatment Considerations for Transplant-Ineligible Multiple MyelomaRadowan A. Elnair, MD, and Sarah A. Holstein, MD, PhD, review literature regarding progress in the management of the transplant-ineligible multiple myeloma in an article published in the journal ONCOLOGY®.
Latest:
Future Perspectives and Unmet Needs in CLLThe panelists conclude their discussion by offering future perspectives on CLL treatment, emphasizing remaining areas of unmet needs in the treatment landscape.
Latest:
Kathleen Moore, MD, on the Key Takeaways of 3 Clinical Trials Examining Niraparib in BRCA-Mutant Ovarian CancerKathleen Moore, MD, discusses findings compiled from 3 clinical trials of niraparib in patients with ovarian cancer.
Latest:
Cross Q&A: The Memorial Sloan-Kettering MavericksThe Moffitt Marrowvingians take their turn questioning the Memorial Sloan Kettering Mavericks on their presented clinical trial data.
Latest:
Later-Line Treatment of Patients with Metastatic NSCLCThe Oncology Brothers and Isabel Preeshagul, DO, MBS, share clinical insights on later-line treatment practices for patients with metastatic non–small cell lung cancer.
Latest:
Emergency Fertility Preservation in a Young Woman With Non-Hodgkin LymphomaA nulliparous woman, age 25 years, had received a diagnosis of non-Hodgkin lymphoma and now presented with stage IIA diffuse large B-cell lymphoma. Due to potential risks of chemotherapy-induced gonadotoxicity and subsequent iatrogenic premature ovarian failure and fertility loss, the patient was referred to the reproductive medicine department for fertility preservation counseling and further management.
Latest:
The Effect of Prior Cancer on Survival of Patients With ThymomaShilong Wu, MD, and co-authors discuss how patients with thymoma are affected by prior cancer history.
